Prospective audit of an aminoglycoside consultative service in a general hospital
- PMID: 1435470
Prospective audit of an aminoglycoside consultative service in a general hospital
Abstract
Objective: To investigate the impact of the introduction of a consultative service on the use, efficiency of dosing and clinical toxicology of the aminoglycoside antibiotics, gentamicin and tobramycin, in a general hospital.
Methods: Two audits were conducted six months and 18 months after the introduction of the consultative service. The audits reviewed the use of drug assay services, the adequacy of drug administration (as measured by serum antibiotic concentrations), indications for prescription, adverse outcomes (by noting markers of nephrotoxicity) and the antibiotic sensitivity of Gram-negative pathogens. The results were compared with the results of an audit conducted before the consultative service was instituted.
Results: There was a significant (P < 0.001 by chi 2 test) increase in the use of assays, with drug assays performed in 67% (first audit) and 77% (second audit) of aminoglycoside courses compared with 48.2% in the pre-intervention audit. Sample timing was greatly improved, with more than 70% of the samples collected at the appropriate times. Assay wastage in terms of uninterpretable assay results decreased significantly (P < 0.001) from 42.9% of total assays to 6.3% at the first audit and 3.8% at the second audit. The percentage of assay results in the desirable range increased significantly (P < 0.001) from 39.1% to 71.9% (first audit) and 75.4% (second audit). Pharmacokinetic recommendations were made in 39.1% and 64% of all aminoglycoside courses during the first and second audits respectively, with clinician acceptance of dosage recommendations at 83.1% and 82.8% respectively. For aminoglycoside courses prescribed for therapeutic reasons, 97.9% (first audit, n = 325) and 98.6% (second audit, n = 280) of indications for use were judged as clinically appropriate. The incidence of suspected aminoglycoside-induced nephrotoxicity was reduced from 8.9% of patients to 1.6% (first audit, P < 0.001) and 2.4% (second audit). Bacterial sensitivity audits showed that the great majority of clinical isolates of target organisms (n = 3523, Year 1 and n = 3385, Year 2) were sensitive to gentamicin (92.2% and 91.5% respectively) and tobramycin (98.1% and 98.8% respectively); these aminoglycosides exceeded all alternative agents in effectiveness, including first and third generation cephalosporins.
Conclusions: The overall results indicate that introduction of the consultative service had a positive impact on the effective use of aminoglycosides, with a marked decrease in clinical toxicity. These influences were shown to persist for at least 18 months. The availability of reliable predictive techniques to reduce toxicity allows active promotion of aminoglycosides as the agents of choice on grounds of efficacy and economy.
Similar articles
-
Prospective audit of aminoglycoside usage in a general hospital with assessments of clinical processes and adverse clinical outcomes.Med J Aust. 1989 Aug 21;151(4):224-32. doi: 10.5694/j.1326-5377.1989.tb115996.x. Med J Aust. 1989. PMID: 2761465
-
Cost savings associated with use of gentamicin versus tobramycin.Am J Hosp Pharm. 1985 Aug;42(8):1745-9. Am J Hosp Pharm. 1985. PMID: 4036972
-
Cost-benefit analysis of an aminoglycoside monitoring service.Am J Hosp Pharm. 1986 May;43(5):1205-9. Am J Hosp Pharm. 1986. PMID: 3087162
-
Antibiotic use in neonatal sepsis.Turk J Pediatr. 1998 Jan-Mar;40(1):17-33. Turk J Pediatr. 1998. PMID: 9722468 Review.
-
Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services.J Clin Pharm Ther. 1987 Oct;12(5):273-91. doi: 10.1111/j.1365-2710.1987.tb00539.x. J Clin Pharm Ther. 1987. PMID: 3119606 Review.
Cited by
-
Minimisation of aminoglycoside toxicity in patients with cystic fibrosis.Thorax. 1996 Apr;51(4):369-73. doi: 10.1136/thx.51.4.369. Thorax. 1996. PMID: 8733487 Free PMC article. Clinical Trial.
-
Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.Antimicrob Agents Chemother. 1998 Jun;42(6):1365-9. doi: 10.1128/AAC.42.6.1365. Antimicrob Agents Chemother. 1998. PMID: 9624477 Free PMC article.
-
Clinical and economic outcomes of pharmaceutical services related to antibiotic use: a literature review.Pharm World Sci. 2007 Jun;29(3):146-63. doi: 10.1007/s11096-006-9042-6. Epub 2007 Feb 2. Pharm World Sci. 2007. PMID: 17273907 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources